Since the advent of COVID-19 mRNA vaccines, mRNA therapeutics has become one of the most promising nucleic acid therapeutics. However, a major challenge now is how to deliver mRNA effectively and increase mRNA expression yield but de-risk potential toxicity to expand its clinical applications beyond vaccines. In the past few years, we have been actively engaged in developing and leveraging on novel lipid nanoparticle (LNP) technologies and mRNA modification techniques to improve the delivery, stability and the production yield of mRNA therapeutics.1-3 Compared to currently commercialized mRNA technologies, our advanced LNPs and mRNA modification techniques enable markedly enhanced